Inovio Pharmaceuticals, Inc.
Company Snapshot: Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative.
- Jun 19 2017 Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
- Jun 15 2017 Inovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution
- Jun 8 2017 Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
- Jun 7 2017 Inovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study